Study Dual GLP-1/GIP Metabolic Regulation with High-Purity Mazdutide Research Peptide

If needed, please add me on WhatsApp at +852 5487 8366 and I’ll send you our product price list.

Dual‑Agonist Breakthrough for Weight and Glucose Control

 Maz (the investigational dual GLP‑1/glucagon receptor agonist) represents a new class of incretin‑based therapies designed to tackle obesity and type 2 diabetes from multiple angles. By simultaneously activating both receptors, Maz enhances satiety, delays gastric emptying, and increases energy expenditure through glucagon‑mediated thermogenesis—a synergistic effect that yields superior weight loss compared to GLP‑1 monotherapy. Clinical trials have demonstrated that Maz can reduce body weight by 12‑15% over 24 weeks, with concomitant improvements in HbA1c, blood pressure, and lipid profiles. Its mechanism also promotes hepatic fat oxidation and reduces steatosis, making it a potential treatment for non‑alcoholic fatty liver disease (NAFLD).

Unlike traditional GLP‑1 agonists, Maz’s glucagon component prevents the adaptive reduction in resting metabolic rate often seen during calorie restriction, leading to sustained weight loss. The peptide is administered once weekly via subcutaneous injec, with a typical dose titration from 2 mg up to 6 mg. Common side effects are gastrointestinal—nausea, vomiting, and diarrhoea—but these are dose‑dependent and usually resolve with gradual up‑titration. Early phase 3 data indicate that Maz may have a favourable cardiovascular profile, with no increased risk of arrhythmias. Additionally, its potential to improve pancreatic beta‑cell function could slow diabetes progression. Researchers are also exploring its use in polycystic ovary syndrome (PCOS) and obstructive sleep apnoea. As a synthetic peptide, Maz is engineered with amino acid substitutions to resist enzymatic degradation, conferring a half‑life suitable for weekly dosing.

 It is currently under regulatory review in several regions, and if approved, it will offer an alternative to existing dual agonists like those targeting GIP/GLP‑1. However, the glucagon component requires careful dosing to avoid hyperglycaemia or hypotension, although the molecule is designed to be glucose‑dependent. Patients with a history of pancreatitis or medullary thyroid carcinoma are advised against use. Maz exemplifies the evolving strategy of multi‑target metabolic modulation, providing a powerful option for those who have not achieved adequate control with conventional therapies. Its future may extend to combination regimens with SGLT2 inhibitors for additive benefits.